Acasti Pharma, Inc. stock is down -4.88% since 30 days ago. The next earnings date is Feb 13, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 72.73% of the previous 10 December’s closed higher than November.
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre, an omega-3 phospholipid therapeutic to treat patients with hypertriglyceridemia.